Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade

被引：0

作者：

Douglas B. Fox

Richard Y. Ebright

Xin Hong

Hunter C. Russell

Hongshan Guo

Thomas J. LaSalle

Ben S. Wittner

Nicolas Poux

Joanna A. Vuille

Mehmet Toner

Nir Hacohen

Genevieve M. Boland

Debattama R. Sen

Ryan J. Sullivan

Shyamala Maheswaran

Daniel A. Haber

机构：

[1] Massachusetts General Hospital Cancer Center and Harvard Medical School,Center for Engineering in Medicine

[2] Broad Institute of Harvard and MIT,Department of Surgery

[3] Massachusetts General Hospital and Harvard Medical School,Department of Medicine

[4] Shriners Hospitals for Children,Department of Biochemistry, School of Medicine and Key University Laboratory of Metabolism and Health of Guangdong

[5] Massachusetts General Hospital and Harvard Medical School,Liangzhu Laboratory

[6] Massachusetts General Hospital and Harvard Medical School,undefined

[7] Howard Hughes Medical Institute,undefined

[8] Southern University of Science and Technology,undefined

[9] Zhejiang University Medical Center,undefined

来源：

npj Precision Oncology | / 7卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Immune checkpoint blockade (ICB) has demonstrated efficacy in patients with melanoma, but many exhibit poor responses. Using single cell RNA sequencing of melanoma patient-derived circulating tumor cells (CTCs) and functional characterization using mouse melanoma models, we show that the KEAP1/NRF2 pathway modulates sensitivity to ICB, independently of tumorigenesis. The NRF2 negative regulator, KEAP1, shows intrinsic variation in expression, leading to tumor heterogeneity and subclonal resistance.

引用

共 50 条

[41] The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients
Zaremba, Anne
Eggermont, Alexander M. M.
Robert, Caroline
Dummer, Reinhardt
Ugurel, Selma
Livingstone, Elisabeth
Ascierto, Paolo A.
Long, Georgina, V
Schadendorf, Dirk
Zimmer, Lisa
EUROPEAN JOURNAL OF CANCER, 2021, 155 : 268 - 280
[42] Immune-related pancreatitis associated with checkpoint blockade in melanoma
Kohlmann, Johannes
Wagenknecht, Daniel
Simon, Jan-Christoph
Ziemer, Mirjana
MELANOMA RESEARCH, 2019, 29 (05) : 549 - 552
[43] Opportunities for Discovery Using Neoadjuvant Immune Checkpoint Blockade in Melanoma
Nair, Uma
Rakestraw, Emily
Beasley, Georgia M.
O'Connor, Margaret H.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (06)
[44] Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma
Jacquelot, Nicolas
Pitt, Jonathan M.
Enot, David P.
Roberti, Maria Paula
Duong, Connie P. M.
Rusakiewicz, Sylvie
Eggermont, Alexander M.
Zitvogel, Laurence
ONCOIMMUNOLOGY, 2017, 6 (08):
[45] Tumour-intrinsic resistance to immune checkpoint blockade
Anusha Kalbasi
Antoni Ribas
Nature Reviews Immunology, 2020, 20 : 25 - 39
[46] Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, Anusha
Ribas, Antoni
NATURE REVIEWS IMMUNOLOGY, 2020, 20 (01) : 25 - 39
[47] Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer
Pillai, Ray
LeBoeuf, Sarah E.
Hao, Yuan
New, Connie
Blum, Jenna L. E.
Rashidfarrokhi, Ali
Huang, Shih Ming
Bahamon, Christian
Wu, Warren L.
Karadal-Ferrena, Burcu
Herrera, Alberto
Ivanova, Ellie
Cross, Michael
Bossowski, Jozef P.
Ding, Hongyu
Hayashi, Makiko
Rajalingam, Sahith
Karakousi, Triantafyllia
Sayin, Volkan I.
Khanna, Kamal M.
Wong, Kwok-Kin
Wild, Robert
Tsirigos, Aristotelis
Poirier, John T.
Rudin, Charles M.
Davidson, Shawn M.
Koralov, Sergei B.
Papagiannakopoulos, Thales
SCIENCE ADVANCES, 2024, 10 (13)
[48] Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, Golnaz
Helmink, Beth A.
Sharma, Padmanee
Wargo, Jennifer A.
CELL, 2021, 184 (21) : 5309 - 5337
[49] Genomic correlates of response and resistance to immune checkpoint blockade
Van Allen, Eliezer M.
CANCER IMMUNOLOGY RESEARCH, 2017, 5 (03)
[50] PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway
Tuo, Lin
Xiang, Jin
Pan, Xuanming
Gao, Qingzhu
Zhang, Guiji
Yang, Yi
Liang, Li
Xia, Jie
Wang, Kai
Tang, Ni
FRONTIERS IN ONCOLOGY, 2018, 8

← 1 2 3 4 5 →